

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-I-010**

You asked:

Please note the figures below relate to June to August 2022.

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] - 90
- Adalimumab [Humira] - 91
- Adalimumab Biosimilars - 398
- Apremilast [Otezla] - 32
- Baricitinib [Olumiant] - 134
- Certolizumab [Cimzia] - 45
- Etanercept [Enbrel] - 100
- Etanercept Biosimilars - 367
- Filgotinib [Jyseleca] - 35
- Golimumab [Simponi] - 28
- Guselkumab [Tremfya] - 0
- Infliximab [Remicade] - 0 (*Issued as stock to rheumatology day unit – patient numbers not available from Pharmacy data)
- Infliximab Biosimilars - <5** (*Issued as stock to rheumatology day unit – patient numbers not available from Pharmacy data)
- Ixekizumab [Taltz] - 10
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] - <5**
- Rituximab Biosimilars - 0 (*Issued as stock to rheumatology day unit – patient numbers not available from Pharmacy data)
- Sarilumab [Kevzara] - <5**
- Secukinumab [Cosentyx] - 76
- Tocilizumab [Ro Actemra] - 101 (*Issued as stock to rheumatology day unit – patient numbers not available from Pharmacy data)
- Tofacitinib [Xeljanz] - 19
- Upadacitinib [Rinvoq] - 68
- Ustekinumab [Stelara] - 12



Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.

- Abatacept [Orencia] - 7
- Adalimumab [Humira] - 16
- Adalimumab Biosimilars - 87
- Apremilast [Otezla] - 31
- Certolizumab [Cimzia] - 16
- Etanercept [Enbrel] - 15
- Etanercept Biosimilars - 53
- Golimumab [Simponi] - 10
- Guselkumab [Tremfya] - 0
- Infliximab [Remicade] - 0
- Infliximab Biosimilars - 0
- Ixekizumab [Taltz] - 5
- Risankizumab [Skyrizi] - 0

* These drugs are also issued as stock, therefore not all data is held centrally on pharmacy systems. To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

** Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

